GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Gross Profit

Amryt Pharma (Amryt Pharma) Gross Profit : $116.6 Mil (TTM As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Gross Profit?

Amryt Pharma's gross profit for the three months ended in Sep. 2022 was $27.4 Mil. Amryt Pharma's gross profit for the trailing twelve months (TTM) ended in Sep. 2022 was $116.6 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Amryt Pharma's gross profit for the three months ended in Sep. 2022 was $27.4 Mil. Amryt Pharma's Revenue for the three months ended in Sep. 2022 was $61.1 Mil. Therefore, Amryt Pharma's Gross Margin % for the quarter that ended in Sep. 2022 was 44.86%.

Amryt Pharma had a gross margin of 44.86% for the quarter that ended in Sep. 2022 => Durable competitive advantage

During the past 12 years, the highest Gross Margin % of Amryt Pharma was 63.35%. The lowest was 33.36%. And the median was 54.49%.

Warning Sign:

Amryt Pharma PLC gross margin has been in long-term decline. The average rate of decline per year is -7.1%.


Amryt Pharma Gross Profit Historical Data

The historical data trend for Amryt Pharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Gross Profit Chart

Amryt Pharma Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.88 10.83 19.39 63.58 116.42

Amryt Pharma Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.25 25.64 28.35 35.17 27.42

Competitive Comparison of Amryt Pharma's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amryt Pharma's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Gross Profit falls into.



Amryt Pharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Amryt Pharma's Gross Profit for the fiscal year that ended in Dec. 2021 is calculated as

Gross Profit (A: Dec. 2021 )=Revenue - Cost of Goods Sold
=222.543 - 106.119
=116.4

Amryt Pharma's Gross Profit for the quarter that ended in Sep. 2022 is calculated as

Gross Profit (Q: Sep. 2022 )=Revenue - Cost of Goods Sold
=61.126 - 33.703
=27.4

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $116.6 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Amryt Pharma's Gross Margin % for the quarter that ended in Sep. 2022 is calculated as

Gross Margin % (Q: Sep. 2022 )=Gross Profit (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=(Revenue - Cost of Goods Sold) / Revenue
=27.4 / 61.126
=44.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Amryt Pharma  (NAS:AMYT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Amryt Pharma had a gross margin of 44.86% for the quarter that ended in Sep. 2022 => Durable competitive advantage


Amryt Pharma Gross Profit Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Amryt Pharma (Amryt Pharma) Business Description

Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).